"We are very excited about our relationship with Affirmative Solutions," said Bill Taylor, MiMedx President and COO. "They have done an extraordinary job in growing their business model. With the significant market potential of our tissue offerings, it is critical that we align with an organization such as Affirmative Solutions that can grow and expand to meet the fast-paced demands of the market."
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix™ and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 35,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the potential impact of the Company's agreement with Affirmative Solutions in
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved